GFS101A
/ GenFleet Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 20, 2022
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=0 | Withdrawn | Sponsor: Zhejiang Genfleet Therapeutics Co., Ltd. | N=96 ➔ 0 | Trial completion date: Apr 2025 ➔ May 2022 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Dec 2024 ➔ May 2022
Combination therapy • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • Oncology • Solid Tumor
December 21, 2021
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2; N=96; Not yet recruiting; Sponsor: Zhejiang Genfleet Therapeutics Co., Ltd.
Clinical • Combination therapy • New P1/2 trial • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1